Alivus Life (ALIVUS) Share News & Alerts
Every article that mentions ALIVUS is analysed by our AI, which assigns a sentiment and tracks the actual price move after the alert fires.
Alivus Life Sciences rises after Q4 PAT climbs 15% YoY to Rs 163 cr
▲ Bullish +2.21%
The stock is impacted by a solid Q4 performance featuring a 14.66% YoY growth in standalone PAT and expanding EBITDA margins to 34.4%. This operational turnaround, especially in its CDMO segment under Nirma's ownership, indicates strong underlying fundamental momentum. In the short to medium-term swing timeframe, this clear fundamental beat is likely to sustain structural buying interest and support a bullish trajectory.
Alivus Life Sciences Q4 PAT climbs 15% YoY to Rs 163 cr
▲ Bullish +3.26%
Alivus Life Sciences reported a healthy 15% year-on-year expansion in its fourth-quarter bottom line, driven by steady operational performance under its new transition structure. This solid profit traction will support a positive near-to-medium term structural re-rating for the stock. Swing and positional traders can expect the asset to witness bullish multi-day price momentum as the market digests the structural margin expansion.
Get real-time alerts for ALIVUS
Add ALIVUS to your portfolio and receive instant AI-powered news alerts on your phone.
Set up free alerts →Explore More
AI Technical Analysis Alert History Other Bullish Stocks Today’s Trending